Digest Network Come funziona
Network
/
Società
Br
Non verificato

Bristol Myers Squibb

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

154 comunicati stampa

Guarda tutti i comunicati
08/09/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
29/08/2026
Eventi
Industria
Scienza
Medicina - Varie
Cardiologia
Sanità
Biotecnologia
Farmaceutica
Salute
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
13/08/2026
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
10/08/2026
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
30/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Scienza
Farmaceutica
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
20/07/2026
Mercato del lavoro
Industria
Sanità
Tecnica
Farmaceutica
Tecnologie Varie
Scienza
Biotecnologia
Software
Salute
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
13/07/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Sanità
Farmaceutica
Salute
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
18/06/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Industria
Scienza
Farmaceutica
Biotecnologia
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
17/06/2026
Titoli e azioni
Salute
Sanità
Farmaceutica
Biotecnologia
Bristol Myers Squibb Announces Dividend
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
Press Release cover image
17/06/2026
Salute
Fitness
Medicina - Varie
Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries
Fonte
Bristol Myers Squibb
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0